Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Insys Must Divest Subsys, Buprenorphine Candidate Products As Part Of Corporate Integrity Agreement
Jun 07 2019
•
By
Derrick Gingery
Insys must exit the opioid space as part of a corporate integrity agreement negotiated with the US Justice and Health and Human Services departments. • Source: Shutterstock
More from Marketing & Advertising
More from Compliance